CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings (loss)	$ (34)	$ 934
Adjustments to reconcile net earnings (loss) to net cash provided (used) by operating activities:
Depreciation and amortization	2,004	1,983
Deferred income taxes	(348)	(383)
Provision for allowances	272	21
Share-based compensation	280	196
Change in fair value of interest rate swaps		(28)
Decommissioning retirement liability	16	16
Gain on sale of marketable securities		(1)
Gain on sale of equipment	(4)
Changes in assets and liabilities:
Trade accounts receivable	(1,344)	(246)
Inventories	(452)	(1,134)
Prepaid expenses and other current assets	(53)	26
Accounts payable	273	583
Accrued salaries, wages and payroll taxes	(1,103)	(1,047)
Refundable income taxes net of income taxes payable	288	914
Other current liabilities	(8)	319
Other	(64)	230
Net cash provided (used) by operating activities	(277)	2,383
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases and construction of property and equipment	(527)	(329)
Cash paid for acquisition of Core Oncology customer base		(4,086)
Proceeds from sale of property and equipment	8
Purchases of marketable securities	(9,008)	(1,708)
Maturities of marketable securities	1,965	1,634
Proceeds from sales of marketable securities		189
Net cash used by investing activities	(7,562)	(4,300)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of borrowings		(834)
Employee stock purchase plan	17	17
Net cash provided (used) by financing activities	17	(817)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(7,822)	(2,734)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	23,589	29,553
CASH AND CASH EQUIVALENTS AT END OF PERIOD	15,767	26,819
SUPPLEMENTARY CASH FLOW DISCLOSURE:
Interest paid	108	182
Income taxes paid (received), net	2	(15)
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Assets acquired from the Core transaction		5,241
Liability for property and equipment acquired	$ 27	$ 39